A late-breaking presentation at AAD 2025 highlights the efficacy and safety of an oral TYK2 inhibitor, showing significant skin clearance in moderate-to-severe psoriasis patients.
InnoCare Pharma announced its novel TYK2 inhibitor ICP-488 deve,loped for the treatment of patients with moderate-to-severe plaque psoriasis, has demonstrated efficacy in treating psoriasis patients at both 6 mg QD and 9 mg QD doses.
Moreover, ICP-488 exhibited favorable safety and tolerability profiles, reinforcing its potential as a valuable treatment option for moderate-to-severe psoriasis patients.
The company released the data at the 2025 American Academy of Dermatology Annual Meeting as a late-breaking oral presentation.
Late-breaking Oral Presentation
In the phase 2, randomized, double-blinded study 129 psoriasis patients were randomized into three groups to receive once daily oral doses of ICP-488 at 6 mg, 9 mg, or placebo for 12 weeks. The primary endpoint was the percentage of subjects who achieved at least a 75% improvement from baseline in the Psoriasis Area and Severity Index score (PASI 75) at week 12.
At week 12, the percentage of patients achieving PASI 75 was significantly superior in the ICP-488 6 mg QD group (77.3%) and the 9 mg QD group (78.6%) than that of the placebo group (11.6%) (P<0.0001); the percentages of subjects achieving PASI 90 and sPGA of 0 (clear) or 1 (almost clear) were also significantly higher in the ICP-488 6 mg QD group (36.4%, 70.5%) and 9 mg QD group (50.0%, 71.4%) compared to the placebo group (0%, 9.3%)(P<0.0001).
All treatment emergent adverse events and treatment-related adverse events and were mild or moderate.
Psoriasis is a chronic, recurrent, inflammatory, and immune-mediated systemic disease influenced by genetic and environmental factors, significantly impacting patients’ quality of life.
ID 97216428 © Hriana | Dreamstime.com
